1. Home
  2. DNLI vs DOCN Comparison

DNLI vs DOCN Comparison

Compare DNLI & DOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • DOCN
  • Stock Information
  • Founded
  • DNLI 2013
  • DOCN 2011
  • Country
  • DNLI United States
  • DOCN United States
  • Employees
  • DNLI N/A
  • DOCN N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • DOCN Retail: Computer Software & Peripheral Equipment
  • Sector
  • DNLI Health Care
  • DOCN Technology
  • Exchange
  • DNLI Nasdaq
  • DOCN Nasdaq
  • Market Cap
  • DNLI 3.3B
  • DOCN 3.5B
  • IPO Year
  • DNLI 2017
  • DOCN 2021
  • Fundamental
  • Price
  • DNLI $20.84
  • DOCN $34.25
  • Analyst Decision
  • DNLI Strong Buy
  • DOCN Buy
  • Analyst Count
  • DNLI 11
  • DOCN 10
  • Target Price
  • DNLI $40.40
  • DOCN $42.11
  • AVG Volume (30 Days)
  • DNLI 867.7K
  • DOCN 681.5K
  • Earning Date
  • DNLI 02-25-2025
  • DOCN 02-19-2025
  • Dividend Yield
  • DNLI N/A
  • DOCN N/A
  • EPS Growth
  • DNLI N/A
  • DOCN N/A
  • EPS
  • DNLI N/A
  • DOCN 0.87
  • Revenue
  • DNLI N/A
  • DOCN $756,564,000.00
  • Revenue This Year
  • DNLI N/A
  • DOCN $14.25
  • Revenue Next Year
  • DNLI $420.35
  • DOCN $13.03
  • P/E Ratio
  • DNLI N/A
  • DOCN $39.20
  • Revenue Growth
  • DNLI 204.74
  • DOCN 12.08
  • 52 Week Low
  • DNLI $14.56
  • DOCN $26.63
  • 52 Week High
  • DNLI $33.33
  • DOCN $44.80
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 35.14
  • DOCN 34.60
  • Support Level
  • DNLI $19.93
  • DOCN $33.59
  • Resistance Level
  • DNLI $21.64
  • DOCN $36.26
  • Average True Range (ATR)
  • DNLI 0.96
  • DOCN 1.32
  • MACD
  • DNLI -0.06
  • DOCN -0.26
  • Stochastic Oscillator
  • DNLI 21.56
  • DOCN 11.17

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About DOCN DigitalOcean Holdings Inc.

DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and Other countries.

Share on Social Networks: